Recent content by gotearsimhere

Dang.

I want to add a little hope for the noxacusis people. I know this thread is about HCN2, but HCN1 is also significant in neuropathic pain. It's not as well proven as HCN2 for noxacusis/tinnitus. A company that has a selective HCN1 blocker is already in the preclinical stage. This shows...

Hi everybody, I just had a talk with one of the 2023 ARO attendees via in-person appointment. I can attest to in-person what @Hazel's observations were about CBT at the ARO. The ARO member I had an appointment with was Dr. William Slattery, of the House Ear Clinic in Los Angeles. For those...

XEN1101 binds to Kv7.4 somewhat well actually, with a Kv7.4 IC50 of 113nm, vs. an established Kv7.2/3 IC50 of 27nm, which is somewhere around 4x less potent, but if tolerable at large doses, some effect would be observed. It would be nice though if Acousia Therapeutics' Kv7.4 activator got...

Hi, this ARO looks particularly good! The presentation regarding the BK channel modulator also fit a theory I already had; glad to see research being published about it. The Presentation is presented by Celeste Ferraguto. SA181 BK Channels as a Therapeutic Target for Auditory Impairments in...